CEPI Funds 3 Bundibugyo Ebola Vaccines as Trials May Still Be 6 to 9 Months Away

3 articles · Updated · Sciencenorway · Jun 30

CEPI on June 1 backed three vaccine candidates targeting the Bundibugyo Ebola variant, with researchers saying the first clinical trials could begin in six to nine months.
Bundibugyo is driving the outbreak in the Democratic Republic of Congo and Uganda, and existing vaccines for the more common Zaire strain are likely to offer little protection.
WHO declared the outbreak an international public health emergency in May; past Bundibugyo outbreaks show up to 1 in 3 infected people die.
Ebola becomes lethal by hijacking immune cells, delaying the body's alarm, then triggering vessel leakage, shock, clotting problems and organ damage, researchers said.
Even so, WHO says international spread remains low because Ebola is not airborne and usually requires direct contact with bodily fluids, though healthcare workers and family caregivers face high risk.

Sources

Sciencenorway2d ago

CEPI Funds Three New Ebola Vaccines for Bundibugyo Variant

Reuters2d ago

Congo Ebola outbreak cases are 'top of the iceberg', coalition says | Reuters

University of Minnesota Twin Cities1d ago

Ebola deaths in Africa top 400 as Uganda reports death of child from Marburg | CIDRAP

7 Sources

With new vaccines on the horizon, is rising community mistrust the true barrier to stopping Ebola?

Why did a US plan for an Ebola facility in Kenya spark fears of a ‘containment colony’?

DRC’s 2026 Bundibugyo Ebola Outbreak: 1,354 Cases, No Licensed Vaccine, and the Fight for Containment

Overview

In early July 2026, the Democratic Republic of the Congo (DRC) faces its 17th Ebola outbreak, declared on May 15 and caused by the Bundibugyo virus, a severe ebolavirus species affecting humans. This outbreak is spreading faster than any previous one, with 1,354 confirmed cases and a daily increase of 26 infections as of June 30. The rapid escalation highlights the urgent need for effective response and preparedness, as the Bundibugyo virus has no licensed vaccines or treatments. The situation underscores the importance of swift public health action and investment in medical countermeasures to control the crisis and prevent further spread.

...